| __timestamp | Amicus Therapeutics, Inc. | Vertex Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 47624000 | 855506000 |
| Thursday, January 1, 2015 | 76943000 | 996170000 |
| Friday, January 1, 2016 | 104793000 | 1047690000 |
| Sunday, January 1, 2017 | 149310000 | 1324625000 |
| Monday, January 1, 2018 | 270902000 | 1416476000 |
| Tuesday, January 1, 2019 | 286378000 | 1754540000 |
| Wednesday, January 1, 2020 | 308443000 | 1829537000 |
| Friday, January 1, 2021 | 272049000 | 3051100000 |
| Saturday, January 1, 2022 | 276677000 | 2540300000 |
| Sunday, January 1, 2023 | 152381000 | 3162900000 |
| Monday, January 1, 2024 | 3630300000 |
Unlocking the unknown
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Vertex Pharmaceuticals Incorporated and Amicus Therapeutics, Inc. have demonstrated contrasting strategies in their R&D investments.
From 2014 to 2023, Vertex Pharmaceuticals has consistently outpaced Amicus Therapeutics in R&D spending. In 2023, Vertex's R&D expenses reached a staggering $3.16 billion, marking a 270% increase from 2014. In contrast, Amicus Therapeutics' R&D spending peaked in 2020 at $308 million, before declining to $152 million in 2023, a 50% drop.
Vertex's robust R&D investment underscores its strategic focus on pioneering treatments, particularly in areas like cystic fibrosis. Meanwhile, Amicus Therapeutics' fluctuating R&D spending reflects a more cautious approach, potentially impacting its long-term innovation pipeline.
Research and Development Investment: Vertex Pharmaceuticals Incorporated vs Regeneron Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Vertex Pharmaceuticals Incorporated and Exelixis, Inc.
Research and Development Expenses Breakdown: Vertex Pharmaceuticals Incorporated vs Viking Therapeutics, Inc.
Vertex Pharmaceuticals Incorporated vs Catalyst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Vertex Pharmaceuticals Incorporated vs Ligand Pharmaceuticals Incorporated: Strategic Focus on R&D Spending
R&D Insights: How Teva Pharmaceutical Industries Limited and Amicus Therapeutics, Inc. Allocate Funds
Research and Development Expenses Breakdown: Intra-Cellular Therapies, Inc. vs Amicus Therapeutics, Inc.
Research and Development: Comparing Key Metrics for Ionis Pharmaceuticals, Inc. and Amicus Therapeutics, Inc.
Comparing Innovation Spending: Alpine Immune Sciences, Inc. and Amicus Therapeutics, Inc.
Viking Therapeutics, Inc. vs Amicus Therapeutics, Inc.: Strategic Focus on R&D Spending
Research and Development Expenses Breakdown: Amicus Therapeutics, Inc. vs HUTCHMED (China) Limited
Analyzing R&D Budgets: Amicus Therapeutics, Inc. vs Mesoblast Limited